Antibody COVID-19 trial paused
Following yesterday’s news that Johnson & Johnson had paused enrolment in its COVID-19-vaccine trial because of “an unexplained illness in a study participant,” drug maker Eli Lilly has now paused a trial of its antibody treatment for people hospitalized with COVID-19 owing to a “potential safety concern”. The trial, sponsored by the US government, was investigating the benefits of treatment with the antibody drug together with the antiviral drug remdesivir, compared with treatment with only remdesivir. Earlier this month, Eli Lilly said it had applied for emergency-use authorization for their drug for people with mild to moderate COVID-19. Pauses in large drug trials are not unusual and do not necessarily suggest a problem with the therapy.
The New York Times | 6 min read
.png)
No hay comentarios:
Publicar un comentario